Eli Lilly & Co. has patented aryl hydrocarbon receptor (AhR) agonists reported to be useful for the treatment of psoriasis, atopic dermatitis, ulcerative colitis, Crohn’s disease, graft-vs.-host disease, rheumatoid arthritis, multiple sclerosis and systemic lupus erythematosus.
Vyrnwy Therapeutics Inc. has disclosed non-receptor tyrosine-protein kinase TYK2 inhibitors reported to be useful for the treatment of autoimmune diseases.
Neuron23 Inc. has synthesized leucine-rich repeat kinase 2 (LRRK2; dardarin) inhibitors reported to be useful for the treatment of Parkinson’s disease.
Haisco Pharmaceutical Group Co. Ltd. has presented hydroxyacid oxidase 1 (HAOX1; HAO1) inhibitors reported to be useful or the treatment of primary hyperoxaluria type 1 and kidney stones.
Nippon Shinyaku Co. Ltd. has patented discoidin domain-containing receptor 1 (DDR1) inhibitors reported to be useful for the treatment of cancer, diabetic nephropathy, hepatic and pulmonary fibrosis, myelofibrosis, nephritis, osteoarthritis and chronic renal failure.
Wigen Biomedicine Technology (Shanghai) Co. Ltd. has synthesized phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer.
Humanwell Healthcare (Group) Co. Ltd. has described sodium channel protein type 10 subunit α (SCN10A; Nav1.8) blockers reported to be useful for the treatment of pain.
Schrodinger Inc. and Takeda Pharmaceutical Co. Ltd. have identified 3C-like proteinase (3CLpro; Mpro; nsp5) inhibitors reported to be useful for the treatment of coronavirus acute respiratory syndrome.
In what represents its first patenting Demon Curonix BV is seeking protection for a system for providing microvesicles to be used in combination with focused ultrasound for drug delivery to the brain.
RSS
